Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Marcia Irene Canto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2193-3032; OpenAlex author ID A5039731184, A5153200583. Sources: ClinicalTrials.gov.

Their work

Papers
45 (first author 8, last author 2)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
180
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: none · 2012: 4 papers · 2013: 5 papers · 2014: 1 paper, 1 trial · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 6 papers · 2021: 4 papers · 2022: 8 papers · 2023: 2 papers · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 45

  1. Association of obstructive sleep apnea with pancreatic cancer in high-risk patients under surveillance in CAPS and PCYST cohorts. Co-author DOI 10.1016/j.pan.2026.10.013↗
  2. Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance-Reply. First author DOI 10.1001/jamaoncol.2024.5522↗
  3. Mild Dilatation of the Main Pancreatic Duct Is a Risk Factor for Progression to Pancreatic Cancer in High-Risk Individuals. Last author DOI 10.1016/j.gastha.2025.100802↗
  4. Personalizing CA125 Levels Using Tumor Marker Variants: A Case-Control Analysis of Diagnostic Performance for Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-25-1050↗
  5. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. First author DOI 10.1001/jamaoncol.2024.1930↗
  6. Twenty-five years of surveillance for familial and hereditary pancreatic ductal adenocarcinoma: Historical perspectives and introduction to the special issue. First author DOI 10.1007/s10689-024-00404-0↗
  7. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. Co-author DOI 10.1200/jco.23.01573↗
  8. Cost–effectiveness of pancreatic cancer screening: Time for a more tailored approach Last author DOI 10.1002/ueg2.12380↗
  9. Screening for pancreatic cancer has the potential to save lives, but is it practical? Co-author DOI 10.1080/17474124.2023.2217354↗
  10. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2020.11.006↗
  11. Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2021.10.008↗
  12. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations Co-author DOI 10.1016/j.gie.2021.12.001↗
  13. American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review… Co-author DOI 10.1016/j.gie.2021.12.002↗
  14. Endoplasmic stress-inducing variants in carboxyl ester lipase and pancreatic cancer risk. Co-author DOI 10.1016/j.pan.2022.08.004↗
  15. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  16. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. First author DOI 10.1053/j.gastro.2022.03.056↗
  17. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. Co-author DOI 10.1093/jnci/djac167↗
  18. COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Co-author DOI 10.1016/j.pan.2021.04.005↗
  19. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. Co-author DOI 10.1097/mpa.0000000000001762↗
  20. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001835↗
  21. Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?—Letter Co-author DOI 10.1158/1940-6207.capr-21-0233↗
  22. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04230-z↗
  23. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2019.10.036↗
  24. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Co-author DOI 10.1016/j.jmoldx.2020.02.010↗
  25. Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. First author DOI 10.1093/jnci/djaa004↗
  26. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  27. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  28. Surveillance for pancreatic cancer in high-risk individuals. First author DOI 10.1002/bjs5.50180↗
  29. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. Co-author DOI 10.1200/jco.18.01489↗
  30. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Co-author DOI 10.1053/j.gastro.2018.05.035↗
  31. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Co-author DOI 10.1073/pnas.1720588115↗
  32. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cance… Co-author DOI 10.1136/gutjnl-2015-311166↗
  33. Screening for Pancreatic Cancer. First author DOI 10.1016/j.suc.2016.07.016↗
  34. A step closer to screening for curable pancreatic cancer? Co-author DOI 10.1038/nrgastro.2015.112↗
  35. Early detection of sporadic pancreatic cancer: summative review. Co-author DOI 10.1097/mpa.0000000000000368↗
  36. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Co-author DOI 10.1158/0008-5472.can-14-0734↗
  37. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Co-author DOI 10.1016/j.cgh.2012.11.016↗
  38. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Co-author DOI 10.1136/gutjnl-2012-303108↗
  39. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Co-author DOI 10.1158/1078-0432.ccr-12-3092↗
  40. Serum miR-1290 as a marker of pancreatic cancer--response. Co-author DOI 10.1158/1078-0432.ccr-13-1899↗
  41. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. Co-author DOI 10.1200/jco.2012.44.7516↗
  42. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer… Co-author DOI 10.1016/j.gie.2011.10.007↗
  43. Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. Co-author DOI 10.1016/j.gie.2012.07.006↗
  44. Pancreatic cancer screening. First author DOI 10.1016/j.gtc.2011.12.001↗
  45. Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-12-1075↗

Trials 2

  1. International CAPS Registry: Pancreas Cancer Cases in Surveillance Programs Principal investigator NCT02703545↗
  2. Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study) Principal investigator NCT00714701↗

Closest collaborators

The 25 strongest of 180 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Goggins · 33 shared papers, 2012–2026 · strength 4.17
  2. Amanda L. Blackford · 10 shared papers, 2018–2026 · strength 1.95
  3. Ralph H. Hruban · 21 shared papers, 2012–2025 · strength 1.85
  4. Jin Peng He · 11 shared papers, 2018–2025 · strength 1.57
  5. Anne Marie Lennon · 14 shared papers, 2012–2024 · strength 1.40
  6. Alison P. Klein · 13 shared papers, 2012–2024 · strength 1.29
  7. Richard Andrew Burkhart · 8 shared papers, 2020–2025 · strength 1.13
  8. Elena M. Stoffel · 11 shared papers, 2018–2024 · strength 1.11
  9. Randall E. Brand · 10 shared papers, 2018–2024 · strength 0.98
  10. Eun Ji Shin · 8 shared papers, 2012–2026 · strength 0.87
  11. Takeichi Yoshida · 5 shared papers, 2022–2025 · strength 0.86
  12. Fay Kastrinos · 8 shared papers, 2019–2024 · strength 0.84
  13. Sapna Syngal · 9 shared papers, 2013–2024 · strength 0.81
  14. Elliot K. Fishman · 8 shared papers, 2014–2024 · strength 0.77
  15. Anil K. Rustgi · 6 shared papers, 2018–2024 · strength 0.60
  16. James R. Eshleman · 5 shared papers, 2018–2024 · strength 0.57
  17. Hans F. A. Vasen · 3 shared papers, 2020–2024 · strength 0.52
  18. Nicholas Jason Roberts · 4 shared papers, 2018–2023 · strength 0.52
  19. Diane M. Simeone · 5 shared papers, 2015–2022 · strength 0.51
  20. Toshiya Abe · 5 shared papers, 2018–2022 · strength 0.51
  21. Bryson W. Katona · 4 shared papers, 2021–2024 · strength 0.51
  22. Elham Afghani · 2 shared papers, 2025–2026 · strength 0.50
  23. James J. Farrell · 4 shared papers, 2020–2024 · strength 0.47
  24. Christopher Lee Wolfgang · 8 shared papers, 2013–2020 · strength 0.43
  25. Helena Saba · 2 shared papers, 2024–2025 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.